A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of BMS-986504 in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion
Latest Information Update: 29 Jul 2025
At a glance
- Drugs MRTX 1719 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 29 Jul 2025 New trial record